Info overloaded, consumers tune out risk info, says survey

Share this article:
Consumers tend to block out risk info in TV and print ads for prescription drugs – particularly those over age 55 – according to a study by ORC Guideline.

The research firm found that 41% of US consumers pay little or no attention to risk info presented by pharma companies in their TV commercials, and half did the same for disclosures in print ads. Respondents over the age of 55 were particularly likely to tune out risk info.

ORC Guideline's chief research officer, Morris Whitcup, said risk info overload is probably to blame. “As consumers utilize a wide variety of sources to learn about prescription medications, it may not be optimal for the FDA to require that pharmaceutical companies include the same details in each of the channels they use to communicate information about their prescription drug products,” said Whitcup.

Asked how they'd prefer to see risk information presented online, 32% said through direct links to an independent website such as WebMD, 27% opted for “a condensed version of risk disclosures a click away,” 26% a direct link to a company site and 25% a link to a government site.

The online survey of 1,045 US adults was conducted October 29-30.


Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...